Why Event-Free Survival is Better than Tumor Response or other Measures of Survival as an Endpoint in Cancer Trials
- 1 April 1996
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 11 (2) , 99-104
- https://doi.org/10.1089/cbr.1996.11.99
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials.Journal of Clinical Oncology, 1991
- Problems in radiographic estimation of response to chemotherapy and radiotherapy in small cell lung cancerCancer, 1988
- Simultaneous Cisplatin Fluorouracil Infusion and Radiation Followed by Surgical Resection in Regionally Localized Stage III, Non–Small Cell Lung CancerThe Annals of Thoracic Surgery, 1987
- Twenty years of MOPP therapy for Hodgkin's disease.Journal of Clinical Oncology, 1986
- Criteria of tumor response used in clinical trials of chemotherapy.Journal of Clinical Oncology, 1985
- Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.Journal of Clinical Oncology, 1984
- Illusion and reality: practical pitfalls in interpreting clinical trials.Journal of Clinical Oncology, 1984
- Biologic response-modifying agents: What is an appropriate phase I?II strategy?Cancer Immunology, Immunotherapy, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958